25.Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care . 2014;37:2926-2933. 26.Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse events with GLP-1 receptor agonists: incidence and consequences. Diabetes Obes Metab . 2017;19:672-681. 27.DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encap- sulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheresproduced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther . 2011;13:1145-1154. 28.Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabeticpatients individually and in groups. Diabetes Care . 2007;30:1364-1369.